文献速递流行病学与生物统计临床试验与 GCP

直立性低血压、高血压治疗与心血管疾病:个体参与者数据的荟萃分析

Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
PubMed 文献 · JAMA · 2023-01-01

该个体参与者数据荟萃分析纳入9项随机试验共29 235例高血压患者,中位随访4年,评估强化降压或活性药物 vs 标准降压或安慰剂对心血管疾病或全因死亡率的影响。结果显示,无论基线有无直立性低血压,强化降压均降低心血管疾病或全因死亡风险,且交互作用不显著;基线站立低血压者中效应无显著差异。

要点

  • 在无基线直立性低血压者中,强化降压或活性治疗降低心血管疾病或全因死亡风险(HR 0.81;95%CI 0.76-0.86)。
  • 在有基线直立性低血压者中,强化降压或活性治疗同样降低该风险(HR 0.83;95%CI 0.70-1.00),交互作用P=0.68。
  • 在无基线站立低血压者中,强化降压或活性治疗降低该风险(HR 0.80;95%CI 0.75-0.85),在有基线站立低血压者中未达统计学显著(HR 0.94;95%CI 0.75-1.18),交互作用P=0.16。

核心结论

  • 在高血压试验参与者中,强化治疗降低心血管疾病或全因死亡风险,且不受直立性低血压影响;在站立低血压者中未见效应差异的证据。

研究设计与样本

  • 基于系统检索MEDLINE、EMBASE和CENTRAL数据库(截至2022年5月13日)的随机试验的个体参与者数据荟萃分析,纳入9项试验共29 235例参与者,中位随访4年,平均年龄69.0岁(SD 10.9),48%为女性。

主要发现

  • 基线时9%有直立性低血压,5%有站立低血压。
  • 无基线直立性低血压者中,强化降压或活性治疗降低心血管疾病或全因死亡风险(HR 0.81;95%CI 0.76-0.86);有基线直立性低血压者中同样降低(HR 0.83;95%CI 0.70-1.00);交互作用P=0.68。
  • 无基线站立低血压者中,强化降压或活性治疗降低心血管疾病或全因死亡风险(HR 0.80;95%CI 0.75-0.85);有基线站立低血压者中未达统计学显著(HR 0.94;95%CI 0.75-1.18);交互作用P=0.16。

关键数值与推荐

  • 直立性低血压定义为从坐位变为站立后收缩压下降至少20 mm Hg和/或舒张压下降至少10 mm Hg。
  • 站立低血压定义为站立收缩压≤110 mm Hg或站立舒张压≤60 mm Hg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are ongoing concerns about the benefits of intensive vs standard blood pressure (BP) treatment among adults with orthostatic hypotension or standing hypotension. OBJECTIVE: To determine the effect of a lower BP treatment goal or active therapy vs a standard BP treatment goal or placebo on cardiovascular disease (CVD) or all-cause mortality in strata of baseline orthostatic hypotension or baseline standing hypotension. DATA SOURCES: Individual participant data meta-analysis based on a systematic review of MEDLINE, EMBASE, and CENTRAL databases through May 13, 2022. STUDY SELECTION: Randomized trials of BP pharmacologic treatment (more intensive BP goal or active agent) with orthostatic hypotension assessments. DATA EXTRACTION AND SYNTHESIS: Individual participant data meta-analysis extracted following PRISMA guidelines. Effects were determined using Cox proportional hazard models using a single-stage approach. MAIN OUTCOMES AND MEASURES: Main outcomes were CVD or all-cause mortality. Orthostatic hypotension was defined as a decrease in systolic BP of at least 20 mm Hg and/or diastolic BP of at least 10 mm Hg after changing position from sitting to standing. Standing hypotension was defined as a standing systolic BP of 110 mm Hg or less or standing diastolic BP of 60 mm Hg or less. RESULTS: The 9 trials included 29 235 participants followed up for a median of 4 years (mean age, 69.0 [SD, 10.9] years; 48% women). There were 9% with orthostatic hypotension and 5% with standing hypotension at baseline. More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among those without baseline orthostatic hypotension (hazard ratio [HR], 0.81; 95% CI, 0.76-0.86) similarly to those with baseline orthostatic hypotension (HR, 0.83; 95% CI, 0.70-1.00; P = .68 for interaction of treatment with baseline orthostatic hypotension). More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among those without baseline standing hypotension (HR, 0.80; 95% CI, 0.75-0.85), and nonsignificantly among those with baseline standing hypotension (HR, 0.94; 95% CI, 0.75-1.18). Effects did not differ by baseline standing hypotension (P = .16 for interaction of treatment with baseline standing hypotension). CONCLUSIONS AND RELEVANCE: In this population of hypertension trial participants, intensive therapy reduced risk of CVD or all-cause mortality regardless of orthostatic hypotension without evidence for different effects among those with standing hypotension.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Juraschek SP, Hu JR, Cluett JL, et al. Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis. JAMA. 2023. PMID: 37847274. doi:10.1001/jama.2023.18497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。